Breaking News —

Paris, May 23 . .- The French Minister of Health, Olivier Véran, assured this Saturday that the use of hydroxychloroquine in hospitals to treat COVID-19 patients will be reconsidered, after the study that shows that it does not offer benefits for these patients and may have side effects.

“After the publication in ‘The Lancet’ of a study warning of the ineffectiveness and risks of some COVID-19 treatments, including hydroxychloroquine, I have requested a study to the inspection of medicamenos to do an analysis”, said the minister on the social network Twitter.

Véran specified that he awaits answers in the next 48 hours and that, after them, they will review the prescription rules of the drug and, failing that, its repeal.

A large observational study suggests that treatment with the antimalarial drug chloroquine or its hydroxychloroquine analog does not offer any benefit to patients with COVID-19 and, conversely, these drugs may cause increased mortality rates and increased cardiac arrhythmias among hospitalized COVID-19 patients.

The “Lancet” study analyzed data from nearly 15,000 COVID-19 patients who received chloroquine or its analog, hydroxychloroquine, and data from 81,000 control patients. The patients are from more than 600 hospitals.

Before these studies, France already restricted this treatment to hospitalized patients and the most severe cases.

However, a prestigious French epidemiologist, Didier Raoult, based in Marseille, defended its effectiveness in coronavirus patients, which received the support of certain political sectors in the country.